Alpelisib is a novel selective inhibitor of the p110α catalytic subunit of PI3K and has recently been approved for treating advanced estrogen receptor-positive, HER2-negative (ER+, HER2-) breast cancer, which is mainly the luminal subtypes[10,11]. Here, PIK3CA is linked to breast carcinoma.